Palisade Bio (7NS0) Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
7NS0 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Palisade Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.01 |
| 52 Week High | US$30.82 |
| 52 Week Low | US$4.75 |
| Beta | 1.29 |
| 1 Month Change | 0% |
| 3 Month Change | 0.12% |
| 1 Year Change | -78.46% |
| 3 Year Change | -99.77% |
| 5 Year Change | n/a |
| Change since IPO | -99.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7NS0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.1% | -0.9% |
| 1Y | -78.5% | 6.6% | 0.3% |
Return vs Industry: 7NS0 underperformed the German Pharmaceuticals industry which returned -17.7% over the past year.
Return vs Market: 7NS0 underperformed the German Market which returned 6.1% over the past year.
Price Volatility
| 7NS0 volatility | |
|---|---|
| 7NS0 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in DE Market | 14.4% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 7NS0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 7NS0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 9 | J. Finley | www.palisadebio.com |
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company’s lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy.
Palisade Bio, Inc. Fundamentals Summary
| 7NS0 fundamental statistics | |
|---|---|
| Market cap | €3.96m |
| Earnings (TTM) | -€12.57m |
| Revenue (TTM) | n/a |
Is 7NS0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7NS0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$13.50m |
| Earnings | -US$13.50m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.42 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 7NS0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/07/03 09:21 |
| End of Day Share Price | 2024/04/05 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Palisade Bio, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Wood | B. Riley Securities, Inc. |
| Kumaraguru Raja | Brookline Capital Markets |
| Aydin Huseynov | Ladenburg Thalmann & Company |